Disc Medicine Director Sells Nearly $4 Million in Stock Under Pre-Arranged Plan

SAN FRANCISCO — Kevin Bitterman, the director of Disc Medicine Inc., sold 49,164 shares of the company's stock on Thursday, generating proceeds of approximately $3.94 million. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, a mechanism that allows corporate insiders to schedule stock sales in advance to avoid accusations of trading on material non-public information.

The sale occurred on September 4, 2026, with the trade settling at a value totaling $3,941,477.88. Disc Medicine, a biotechnology firm focused on developing treatments for spinal disorders, has seen its leadership engage in various equity transactions as part of standard executive compensation and diversification strategies. The use of a Rule 10b5-1 plan indicates that the timing and price of the sale were determined by an algorithm or schedule established prior to the execution date, rather than being driven by immediate market conditions or internal company developments at the time of the trade.

Bitterman's divestiture represents a significant liquidation event for the director. While the specific terms of his trading plan, including when it was originally adopted and the total number of shares scheduled for sale under the agreement, were not detailed in the immediate filing, the transaction adheres to federal securities regulations designed to provide a safe harbor for insiders. Such plans are common among executives who wish to reduce their holdings without appearing to react to confidential company data.

The biotechnology sector has faced volatility in recent months as investors weigh clinical trial results against broader market trends. Disc Medicine's stock performance during the period leading up to the sale remains a key metric for analysts tracking the company's valuation. The sale does not indicate a change in Bitterman's role or responsibilities within the organization, nor does it suggest an immediate shift in the company's strategic direction.

Regulatory filings regarding insider trading are mandatory under U.S. securities laws and must be submitted to the Securities and Exchange Commission within specific timeframes following the transaction. These disclosures provide transparency for shareholders and the public regarding the equity movements of company officers and directors. The filing confirms that the sale was conducted in compliance with all applicable rules governing insider transactions.

As the market digests the news, investors will continue to monitor Disc Medicine's pipeline and future financial reports. Questions remain regarding whether this transaction marks the conclusion of Bitterman's trading plan or if further sales are scheduled under the same agreement. The company has not issued a separate statement regarding the sale beyond the required regulatory disclosure.